5-Amino-1MQ Reference

NNMT inhibitor (small molecule, not a peptide) · Research compound

ClassNNMT inhibitor (small molecule, not a peptide)
StatusResearch compound
Typical vials50 mg, 100 mg
Dose range25 mg to 50 mg
FrequencyDaily
Half-lifeNo human data
Dosing unitmilligrams
RouteOral (typical) or subcutaneous

What 5-Amino-1MQ is

5-Amino-1MQ is the odd one out on this page: a small-molecule methylquinolinium, not a peptide. It inhibits NNMT, an enzyme that drains cellular NAD+ precursors and is overactive in fat tissue, which is why rodent studies showing fat-mass loss and muscle-quality improvements made it a community favorite for metabolic stacks. All of that evidence is preclinical.

Most community use is oral capsules, where it shows up alongside GLP-1 protocols; vials for injection exist but are the minority form. It appears in the PTDS testing dataset because vendors sell both forms and purity questions apply either way.

Reconstitution math

Concentration is everything: the same 50 mg vial gives a different draw for every amount of bacteriostatic water you add. The table uses the common 2 mL setup for each vial size, which puts every unit on a U-100 insulin syringe at 250 mcg for the default vial. Dashes mark draws too small to measure or larger than the syringe.

VialBAC waterConcentration25 mg50 mg
50 mg2 mL25 mg/mL100 u-
100 mg2 mL50 mg/mL50 u100 u
5-Amino-1MQ syringe drawsDRAW GUIDEEach dose as a filled syringe50 mg vial + 2 mL bacteriostatic water = 2.5 mg per 0.1 mL (10 units).0102030405060708090100units on a U-100 insulin syringe25 mg100 u (1 mL)peprecon.com
Draw positions for the common doses at the default setup.

Dosing and protocol

Community protocol: 50 to 150 mg daily, usually oral capsules; injectable use runs 25 to 50 mg.

Oral community dosing runs 50 to 150 mg daily. For the injectable form, 25 to 50 mg subcutaneously daily is the common pattern; on a 50 mg vial with 2 mL of water, 25 mg is a full 1 mL draw, so injectable users often reconstitute with less water.

Pharmacokinetics

No curve is shown, on purpose.

5-Amino-1MQ has no published human pharmacokinetics by any route; the entire evidence base is cell and rodent work on NNMT inhibition. There is nothing to plot.

Storage and handling

Lyophilized vials keep best cold, dark, and dry; refrigeration is the community default and freezing lyophilized powder is common for long holds. After reconstitution, refrigerate at 2 to 8 C, do not freeze the solution, and date the vial. Bacteriostatic water's preservative keeps multi-dose use practical for about 28 days by USP convention, though our 120-day stability study found the preservative itself outlasts that window.

Got a certificate of analysis with your vial? Run it through our COA Reader: it reads the report in plain English, checks purity and mass against the label claim, and links the testing lab’s own verification page. Our guide to reading a COA explains what the numbers do and do not tell you.

Sources

  1. Neelakantan et al., Small-molecule NNMT inhibitors increase fatty-acid oxidation, Biochem Pharmacol 2018
  2. Dimet-Wiley et al., NNMT inhibition in aged muscle function, J Cachexia Sarcopenia Muscle 2024

Related references: NAD+ · MOTS-c